Guerbet S.A (GBT) | Financial Analysis & Statements
Guerbet S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Income Metrics
Balance Sheet Metrics
Total Assets
930.0M
Total Liabilities
669.9M
Shareholders Equity
260.1M
Debt to Equity
2.58
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
Guerbet S.A Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 798.7M | 851.1M | 795.7M | 769.5M | 735.9M |
| Cost of Goods Sold | 232.5M | 224.4M | 206.8M | 211.2M | 218.4M |
| Gross Profit | 566.2M | 626.7M | 588.9M | 558.3M | 517.5M |
| Gross Margin % | 70.9% | 73.6% | 74.0% | 72.6% | 70.3% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | 13.7M | 14.8M | 15.7M | 16.4M | 13.6M |
| Other Operating Expenses | 208.2M | 207.8M | 190.9M | 182.4M | 164.4M |
| Total Operating Expenses | 221.9M | 222.6M | 206.6M | 198.8M | 178.0M |
| Operating Income | 8.1M | 48.8M | 39.2M | 42.9M | 39.4M |
| Operating Margin % | 1.0% | 5.7% | 4.9% | 5.6% | 5.4% |
| Non-Operating Items | |||||
| Interest Income | 371.0K | 283.0K | 123.0K | 34.0K | 59.0K |
| Interest Expense | 19.8M | 20.5M | 10.6M | 4.6M | 5.3M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -109.6M | 19.4M | 30.8M | -28.4M | 29.0M |
| Income Tax | 3.1M | 5.9M | 8.6M | 12.7M | -3.7M |
| Effective Tax Rate % | 0.0% | 30.4% | 28.0% | 0.0% | -12.6% |
| Net Income | -112.7M | 13.5M | 22.2M | -41.1M | 32.6M |
| Net Margin % | -14.1% | 1.6% | 2.8% | -5.3% | 4.4% |
| Key Metrics | |||||
| EBITDA | 168.8M | 114.3M | 101.2M | 146.8M | 91.3M |
| EPS (Basic) | - | €1.07 | €1.89 | €-3.25 | €2.59 |
| EPS (Diluted) | - | €1.07 | €1.89 | €-3.25 | €2.58 |
| Basic Shares Outstanding | - | 12603500 | 12641115 | 12616390 | 12616390 |
| Diluted Shares Outstanding | - | 12603500 | 12641115 | 12616390 | 12616390 |
Income Statement Trend
Guerbet S.A Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 115.5M | 50.2M | 51.3M | 41.7M | 115.7M |
| Short-term Investments | 28.3M | 36.2M | 41.5M | 41.2M | 42.9M |
| Accounts Receivable | 145.3M | 172.9M | 149.5M | 121.2M | 118.8M |
| Inventory | 294.5M | 301.2M | 305.2M | 272.5M | 202.0M |
| Other Current Assets | 4.1M | 2.1M | 9.0M | 10.5M | 6.0M |
| Total Current Assets | 600.7M | 590.0M | 581.6M | 509.7M | 495.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 112.2M | 111.1M | 104.0M | 99.5M | 90.8M |
| Goodwill | 90.3M | 135.5M | 125.9M | 125.4M | 228.4M |
| Intangible Assets | 32.8M | 77.9M | 68.3M | 70.4M | 148.8M |
| Long-term Investments | - | - | 900.0K | 900.0K | - |
| Other Non-Current Assets | - | - | - | - | 1.0K |
| Total Non-Current Assets | 329.3M | 447.3M | 443.6M | 430.0M | 505.4M |
| Total Assets | 930.0M | 1.0B | 1.0B | 939.6M | 1.0B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 85.3M | 95.1M | 92.9M | 103.7M | 81.0M |
| Short-term Debt | 49.1M | 44.5M | 12.7M | 33.4M | 33.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.0K | - | - | - | -2.0K |
| Total Current Liabilities | 241.2M | 254.5M | 229.2M | 239.6M | 236.9M |
| Non-Current Liabilities | |||||
| Long-term Debt | 392.1M | 350.6M | 374.0M | 278.4M | 299.7M |
| Deferred Tax Liabilities | 5.7M | 6.4M | 9.4M | 9.9M | 15.2M |
| Other Non-Current Liabilities | - | 1.0K | -1.0K | - | - |
| Total Non-Current Liabilities | 428.7M | 391.2M | 417.7M | 320.5M | 358.9M |
| Total Liabilities | 669.9M | 645.7M | 647.0M | 560.1M | 595.7M |
| Equity | |||||
| Common Stock | 12.6M | 12.6M | 12.6M | 12.6M | 12.6M |
| Retained Earnings | -108.3M | 16.1M | 23.9M | -41.1M | 32.6M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 260.1M | 391.6M | 378.3M | 379.6M | 405.1M |
| Key Metrics | |||||
| Total Debt | 441.2M | 395.1M | 386.8M | 311.9M | 333.1M |
| Working Capital | 359.5M | 335.5M | 352.4M | 270.1M | 258.6M |
Balance Sheet Composition
Guerbet S.A Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -112.7M | 13.5M | 22.2M | -41.1M | 32.6M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | -680.0K | 717.0K | 205.0K | -399.0K | 610.0K |
| Working Capital Changes | 12.2M | -14.1M | -54.1M | -80.5M | -2.9M |
| Operating Cash Flow | -81.3M | 20.6M | -21.1M | -117.5M | 35.6M |
| Investing Activities | |||||
| Capital Expenditures | -29.3M | -30.8M | -40.8M | -42.6M | -36.7M |
| Acquisitions | - | 0 | -2.7M | 0 | - |
| Investment Purchases | - | -1.2M | -2.4M | -3.5M | -7.4M |
| Investment Sales | 1.6M | 2.4M | 973.0K | 0 | 1.3M |
| Investing Cash Flow | -36.2M | -29.7M | -48.2M | -49.4M | -41.5M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | -6.3M | -6.3M | -10.7M | -8.8M |
| Debt Issuance | 87.4M | 13.3M | 445.5M | 2.4M | 6.6M |
| Debt Repayment | -47.3M | -14.1M | -383.9M | -35.7M | -34.4M |
| Financing Cash Flow | 40.1M | -7.1M | 55.4M | -44.0M | -36.0M |
| Free Cash Flow | 44.5M | 24.2M | -26.6M | -20.1M | 67.0M |
| Net Change in Cash | -77.4M | -16.2M | -13.9M | -210.9M | -41.9M |
Cash Flow Trend
Guerbet S.A Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
13.77
Forward P/E
4.96
Price to Book
0.47
Price to Sales
0.16
PEG Ratio
4.96
Profitability Ratios
Profit Margin
-13.56%
Operating Margin
-1.70%
Return on Equity
-34.58%
Return on Assets
0.51%
Financial Health
Current Ratio
2.49
Debt to Equity
169.65
Beta
0.91
Per Share Data
EPS (TTM)
€-8.91
Book Value per Share
€21.17
Revenue per Share
€63.31
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| GBT | 127.3M | 13.77 | 0.47 | -34.58% | -13.56% | 169.65 |
| Eurobio Scientific | 229.6M | 108.64 | 1.33 | 2.24% | 2.90% | 0.19 |
| Median Technologies | 188.6M | -3.61 | - | 74.31% | -94.04% | -1.15 |
| Affluent Medical | 122.2M | -8.37 | 5.24 | -62.51% | -279.97% | 110.96 |
| Mauna Kea | 37.4M | -1.17 | -1.37 | 42.66% | -127.03% | -1.35 |
| Diagnostic Medical | 34.5M | -133.50 | 2.16 | -11.62% | -3.37% | 138.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.